Division of Nephrology-Hypertension, VA San Diego Healthcare System, University of California San Diego, San Diego, CA, USA.
Clin Exp Pharmacol Physiol. 2013 Feb;40(2):138-47. doi: 10.1111/1440-1681.12036.
Acute kidney injury (AKI) is a major burden on health systems and may arise from multiple initiating insults, including ischaemia-reperfusion injury, cardiovascular surgery, radiocontrast administration and sepsis. Similarly, the incidence and prevalence of chronic kidney disease (CKD) continues to increase, with significant morbidity and mortality. Moreover, an increasing number of AKI patients survive to develop CKD and end-stage renal disease. Although the mechanisms for the development of AKI and progression to CKD remain poorly understood, initial impairment of oxygen balance likely constitutes a common pathway, causing renal tissue hypoxia and ATP starvation that, in turn, induce extracellular matrix production, collagen deposition and fibrosis. Thus, possible future strategies for one or both conditions may involve dopamine, loop diuretics, atrial natriuretic peptide and inhibitors of inducible nitric oxide synthase, substances that target kidney oxygen consumption and regulators of renal oxygenation, such as nitric oxide and heme oxygenase-1.
急性肾损伤(AKI)是对卫生系统的一个重大负担,可能由多种起始损伤引起,包括缺血再灌注损伤、心血管手术、放射性造影剂给药和脓毒症。同样,慢性肾脏病(CKD)的发病率和患病率也在持续上升,具有显著的发病率和死亡率。此外,越来越多的 AKI 患者存活下来并发展为 CKD 和终末期肾病。尽管 AKI 的发展和向 CKD 进展的机制仍不清楚,但氧平衡的初始损害可能构成一个共同途径,导致肾脏组织缺氧和 ATP 饥饿,进而诱导细胞外基质产生、胶原沉积和纤维化。因此,针对一种或两种情况的未来可能策略可能涉及多巴胺、袢利尿剂、心房利钠肽和诱导型一氧化氮合酶抑制剂,这些物质靶向肾脏耗氧量和肾脏氧合调节剂,如一氧化氮和血红素加氧酶-1。